SMC expands guidance for Lokelma to emergency care settings
New access to treatment involves adult patients with hyperkalaemia across Scotland
Read Moreby John Pinching | Nov 8, 2022 | News | 0
New access to treatment involves adult patients with hyperkalaemia across Scotland
Read Moreby Selina McKee | Sep 8, 2020 | News | 0
The decisions bring a raft of new treatment options for conditions including epilepsy, depression and cancer
Read Moreby Selina McKee | May 4, 2020 | News | 0
Update provides dosing regimen specifically for hyperkalaemia in patients with end-stage renal disease on stable haemodialysis
Read Moreby Selina McKee | Apr 27, 2020 | News | 0
The drug’s label now includes a dosing regimen specifically to treat hyperkalaemia in patients with end-stage renal disease on stable hemodialysis
Read Moreby Anna Smith | Jul 30, 2019 | News | 0
The news comes shortly after AZ announced positive results from a late-stage trial of the drug.
Read Moreby Selina McKee | Oct 29, 2018 | News | 0
Preliminary guidelines released by the National Institute for Health and Care Excellence do not recommend NHS funding for hyperkalaemia treatments Lokelma and Veltassa.
Read Moreby Selina McKee | May 21, 2018 | News | 0
US regulators have finally issued a green light for AstraZeneca’s Lokelma as a treatment for hyperkalaemia – elevated potassium levels in the blood – in adult patients.
Read Moreby Selina McKee | Mar 23, 2018 | News | 0
AstraZeneca’s Lokelma has been approved in Europe to treat hyperkalaemia in adult patients.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
